Dendritic cells are the most potent antigen-presenting cells, but their roles in blood-stage malaria-infection are not fully understood. We examined the effects of Flt3 ligand, a cytokine which induces dendritic cell production, in vivo on the course of infection with Plasmodium berghei ANKA. Mice treated with Flt3 ligand showed preferential expansion of CD8 + dendritic cells and granulocytes, lower parasitemia, and were protected from the development of lethal experimental cerebral malaria (ECM). Rag2 knock-out mice treated with Flt3 ligand also showed inhibition of parasitemia, suggesting that this protection was, at least in part, due to stimulation of innate immunity. However, it was unlikely that the inhibition of ECM was simply due to the reduction in parasitemia.
Introduction
Malaria is one of the most serious infections in the world, and is responsible for more than one million deaths each year. Infection with Plasmodium falciparum induces a wide range of severe pathologies including cerebral malaria (CM), one of the major causes of mortality of this important parasite (14, 29, 36) . Infection with Plasmodium berghei ANKA (PbA), a rodent malaria parasite, induces neurological symptoms and death in C57BL/6 and CBA mice, and is widely used as a mouse model of experimental cerebral malaria (ECM) (8) (15, 17, 19, 20, 25, 33) . However, DCs also play an important role in the pathogenesis of ECM, a T cell-dependent disease. It was previously shown that depletion of conventional DCs, but not plasmacytoid DCs, resulted in reduced activation of malaria-specific T cells and inhibition of ECM development (10).
The regulatory function of DCs in the pathogenesis of CM, however, is not completely understood.
Flt3 ligand (Flt3L) is an important cytokine for the differentiation and homeostasis of DCs (32) . DCs differentiate from flt3 + progenitor cells at a steady state (16).
Administration of Flt3L induces a drastic increase of DCs in spleen and lymph nodes (21).
In contrast, the lack of Flt3L leads to severe reductions in DC numbers in many tissues 
Materials and Methods

Mice and plasmid transduction
Rag-2 -/-mice of C57BL/6 background (31) were provided by Dr. Y. Yoshikai (Kyushu University, Fukuoka, Japan), and were maintained in the Laboratory Animal Center for Animal Research at Nagasaki University. C57BL/6 mice were purchased from SLC (Hamamatsu, Japan). The animal experiments reported herein were conducted according to the Guidelines of the Laboratory Animal Center for Biomedical Research at Nagasaki University.
The coding sequence for the extracellular domain (amino acids from 1 to 189) of mouse Flt3L was obtained by PCR from cDNA prepared from mouse spleen using primer pairs 5'-GATCCACCATGACAGTGCTGGCGCCAGC-3' and 5'-GATCTACTGCCTGGGCCGAGGCTCTG-3'. After confirming the sequence, the PCR product was cloned into pCAGGS, resulting in pCAGGS-Flt3L. The plasmid was purified using PureYield TM Plasmid Maxiprep System (Promega, Madison, WI), and its endotoxin level was 2.43 EU (equivalent to 0.55ng endotoxin) per g DNA as determined by Limulus test (Wako, Osaka, Japan). A solution containing the plasmid (5g in PBS) was injected into mice using the hydrodynamics method, as previously described (12 pulsed with RBC lysate (1mg/ml) for two hours. The levels of IFN-in the supernatant were determined by ELISA as described (25).
Preparation of brain-sequestered leukocytes and RBCs
Mice were sacrificed 6 days after PbA-infection, and brain-sequestered leukocytes were prepared as previously described with slight modification (24). Briefly, euthanized mice were perfused intracardially with PBS, and brains were removed. Brains were crushed and treated with collagenase (100U/ml) at 37℃ for 15 min. APC-anti-CD45 mAbs and were analyzed using FACSCanto II. The proportion of pRBC was determined by microscopic examination in a manner similar to standard blood films.
The number of pRBC in brains was calculated by multiplying the number of RBCs with the proportion of pRBC.
Depletion of neutrophils
The hybridoma cell line secreting RB6-8C5 mAb (anti-Gr1) was provided by Dr. H. Asao (Yamagata University, Yamagata, Japan) (7). Cells were cultured using CELLine system (BD Biosciences) and the supernatant was purified using a HiTrap protein G HP column (GE healthcare). To deplete neutrophils, mice received i.p. injection of mAb (50 g) two days before the infection. Anti-Gr1 mAb RB6-8C5 is specific for both Ly6C and Ly6G (11) . Since Ly6C is expressed on some T cells, we used 50 g mAb, that depleted >99% Ly6G + granulocytes, while maintaining the majority of T cells (>85%) two days after the treatment. Under the conditions used, we estimated that the effect on the Ly6C + population was minimal.
Statistics
Results are expressed as means ± SD. Statistical analysis was performed using
Mann-Whitney test between two experiment groups or the logrank test for survival, and the data were calculated using GraphPad Prism software (version 4.0). Differences with P<0.05 were considered significant.
Results
Prevention of cerebral malaria by Flt3L-treatment
We introduced a plasmid encoding mouse Flt3L into C57BL/6 mice using the hydrodynamics method to stimulate expansion of DCs in vivo. The serum concentration of Flt3L was significantly increased one week after Flt3L-treatment (Fig. 1A) . The numbers of DCs and granulocytes in the spleen of treated mice were significantly increased as previously reported (38), while numbers of NK cells and macrophages were not increased (Fig. 1B) . 1D ). DCs from Flt3L-treated mice stimulated IFN- production of malaria-specific CD8 + T cells much better than control DCs, which is consistent with the increase in the proportion of CD8 + DCs in Flt3L-treated mice (9, 19) .
To determine the effect of Flt3L on the pathogenesis of PbA-infection, Flt3L-treated and untreated mice were infected with PbA, and their survival was monitored ( Fig. 2A) . Most
coma. In contrast, Flt3L-treated mice were clearly protected from lethal CM. Mild symptoms of ECM such as fur ruffling or hunching were observed in some of the Flt3L-treated mice within ten days, but none succumbed to death during this period. The level of parasitemia was significantly reduced in Flt3L-treated mice 5 days after infection with PbA, but continued to increase to more than 50% within 2 weeks of the infection.
The few control mice that survived the critical period of ECM also showed a similar increase in parasitemia. We tested various doses of the Flt3L-plasmid and found an inverse correlation between the number of DCs in the spleen and the levels of parasitemia 5 days after infection (Supplemental Fig. 1 ). In addition, mice that were transfered with Flt3L-induced DCs showed reduced parasitemia levels, suggesting that these DCs were directly involved in anti-malaria effects of Flt3L-treatment during early period of the infection ( Supplementary Fig. 2 ). To visualize the integrity of the blood brain barrier in infected mice, the leakage of dye in the brain was examined after i.v. injection of Evans blue (Fig. 2B) . In control mice, brains were stained with the dye, suggesting the blood brain barrier was impaired. However, the brains of Flt3L-treated mice showed little leakage, indicating that the integrity of blood brain barrier was maintained. These results suggest that Flt3L-treatment effectively prevented the development of ECM.
Since parasitemia levels were inhibited during the early period of the infection in Flt3L-treated mice, we suspected that innate immune responses might be responsible for controlling the parasitemia. To examine this possibility, Rag2 -/-mice, which lack both T and B cells, were treated with Flt3L and were infected with PbA ( Fig. 2C ). The levels of parasitemia in Flt3L-treated Rag2 -/-mice were lower than parasitemia levels in untreated mice during the early period of the infection, suggesting that enhancement of innate immunity by Flt3L-treatment effectively limited the expansion of PbA during this period.
However, this effect was transient and was not sufficient for protection as the parasitemia levels continued to rise in infected Rag2 -/-mice. Since DCs can phagocytose
Plasmodium-infected RBC (15), we examined the possibility that Flt3L-expanded DCs phagocytosed pRBC. Flt3L-treated and untreated wild-type C57BL/6 mice were infected with PbA-GFP, and splenocytes were examined 5 days later using flow cytometry ( Thus, we treated mice with Flt3L 4 days after the infection (Fig. 2G ). Two days after Flt3L-treatment, when serum Flt3L levels significantly increased (1.71+ 0.79 ng/ml in treated vs. 0.32 + 0.02 ng/ml in untreated mice), the parasitemia level was not reduced, suggesting that Flt3L did not directly inhibit parasite growth. Collectively, we concluded that it was unlikely that inhibition of ECM development in Flt3L-treated mice was simply due to the inhibition of parasitemia or due to the change in systemic IFN- response.
Expansion and activation of CD8 + T cells in Flt3L-treated PbA-infected mice.
Since ECM is a T cell-dependent disease, we next examined the number and phenotype of T cells 5 days after infection with PbA. The number of CD4 + and CD8 + T cells did not change significantly after PbA infection in untreated mice, but increased dramatically in both spleen and peripheral blood after PbA infection in Flt3L-treated mice (Fig. 3A) . In particular, the increase in CD8 + T cells was prominent. To investigate the function of these CD8 + T cells, they were stimulated with DC pulsed with pRBC lysate. CD8 + Ｔ cells from Flt3L-treated mice produced IFN- in response to malaria antigen at levels similar to or higher than those from untreated mice, suggesting that the priming and IFN- production of CD8 + T cells specific for malaria antigen was not impaired in Flt3L-treated mice. (Fig. 3B ).
We next examined the phenotypes of CD8 + T cells, since they are critical for the pathogenesis of ECM. Interestingly, a large population of CD8 + T cells was found to express CD11c in mice infected with PbA, while CD11c was not significantly induced in CD4 + T cells upon PbA infection (Fig. 4A ). The majority of CD11c + CD8 + T cells co-expressed CD44, suggesting that they were recently activated effector T cells (Fig.   4B ). CD11c is a well-known marker of DCs, but it was previously reported that some activated CD8 + T cells express CD11c (4, 13, 18 (Fig. 4F) . The number of brain-sequestered pRBCs was strikingly reduced in Flt3L-treated mice, consistent with protection from lethal ECM.
Roles of Treg and granulocytes in Flt3L-treated mice
To investigate the possible role of regulatory CD4 + T cells (Treg) in the differential activation of CD8 + T cells in Flt3L-treated mice, we first examined the number of unlikely that the function of Treg in these two groups of mice is significantly different.
Therefore, it is unlikely that the differences in CD8 + T cells between Flt3L-treated and untreated mice are due to differences in Treg.
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Treatment of mice with Flt3L increased the number of granulocytes and DCs in the spleen (Fig. 1B) . The role of granulocytes in malaria pathogenesis was previously evaluated; two studies reported that the depletion of granulocytes by antibody-treatment did not significantly affect the level of parasitemia, but prevented the development of ECM (7, 30) , while one study reported that granulocyte depletion in the effector phase did not affect ECM pathogenesis (3). Thus, we evaluated the role of granulocytes in the inhibition of ECM and parasitemia (Fig. 6) . Depletion of granulocytes with anti-Gr1 mAb (>99%) prior to the infection did not significantly affect the levels of parasitemia in both control and Flt3L-treated mice, and did not alter the inhibitory effect of Flt3L on the development of ECM. Therefore, we concluded that inhibition of ECM by Flt3L-treatment was not due to the increase in the number of granulocytes. We employed the hydrodynamic method to induce Flt3L in vivo, and we observed an increase in the number of DCs in the spleen. The proportion of CD8 + DCs was increased to more than 50% of all DCs, consistent with the previous report that used adenoviral vector expressing recombinant Flt3L (23). These DCs expressed MHC and co-stimulatory molecules at levels similar to controls, and were superior in cross-presenting malaria antigens to specific CD8 + T cells, as previously reported (19).
After infection of Flt3L-treated mice with PbA, a significant reduction of parasitemia levels was observed during the initial period of the infection, suggesting that Flt3L-treated mice were more protected than untreated mice. We speculate that this initial protective response was mainly due to enhancement of innate immunity, since we observed a similar reduction in parasitemia levels in Flt3L-treated Rag2 -/-mice, which lack both T and B cells. We suspect that the expansion of DCs contribute to reduced parasitemia through DC phagocytosis of pRBC. Granulocytes may be less involved, since the parasitemia levels were not significantly increased in mice depleted of granulocytes. This protection, however, was not long-lasting, and parasitemia rose in Flt3L-treated mice until they succumbed to death.
To investigate the mechanisms that lead to the prevention of ECM by Flt3L-treatment, we studied the effects of Flt3L-treatment on T cells, since T cells play an instrumental role in the pathogenesis of ECM. We first observed the marked increase in the number of CD8 + T cells in the spleen of Flt3L-treated mice after infection with PbA. Since CD8 + DCs preferentially increased in Flt3L-treated mice, we speculate that these DCs cross-presented and activated malaria-specific CD8 + T cells. These CD8 + T cells were found to produce IFN- in response to PbA antigens at levels equal to or even higher than those from untreated mice (Fig. 3B) , indicating that priming and IFN- production of malaria-specific CD8 + T cells was not impaired in Flt3L-treated mice. However, phenotypic study of the CD8 + T cells in the spleen showed some interesting features.
First, we unexpectedly found that most CD8 + T cells in PbA-infected mice expressed
CD11c, an integrin molecule that is often considered a marker of DCs. CD11c expression was also observed on CD8 + T cells after infection with another rodent malaria parasite, Plasmodium yoelii (data not shown), and was previously reported in intraepithelial lymphocytes (IEL) and recently activated CD8 + T cells in virus-infected mice (4, 13, 18).
IEL from germ free mice did not express CD11c, and bacterial colonization induced 
Figure 5
Treg are unlikely to be involved in inhibition of CD8 + T cell activation in Flt3L-treated mice after PbA infection. The correlation between the number of DCs and anti-malaria effect in mice treated with Flt3L. were determined five days after infection (B), and survival of the mice was monitored (C).
Supplemetal Figure 2:
Inhibition of the parasitemia by inoculation with Flt3L-induced DCs.
Flt3L-DCs were purified from C57BL/6 mice that were inoculated with Flt3L-plasmid (5μg/mouse) by hydrodynamics method. Seven days later, splenic DCs were purified by cell sorting using 
